<DOC>
	<DOCNO>NCT02609737</DOCNO>
	<brief_summary>This study 3 step everyone 3 step do . The overall goal see new experimental drug safe image ( step 1 ) treat neuroendocrine tumor ( step 2 3 ) .</brief_summary>
	<brief_title>Theranostics Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 177Lu-DOTA-JR11 Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Ability understand willingness sign write informed consent document Adults ≥ 18 year old Histologically cytologically confirm metastatic and/or unresectable progressive , well differentiate carcinoid pancreatic NET carcinoid Progressive metastatic disease define one following , occur within 6 month study entry : At least 20 % increase radiologically clinically measurable disease Appearance new lesion Symptomatic disease ( include worsen hormonal symptom symptom related tumor burden ) Measurable disease define RECIST 1.1 . At least one metastasis must show uptake 111InDTPAoctreotide SPECT high physiologic radiotracer uptake liver ECOG performance status ≤ 2 ( Karnofsky ≥ 60 % ) Patients must normal organ marrow function define : Leukocytes ≥ 3.0 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Hemoglobin ≥ 9.0 g/dL Platelets ≥ 200 x 10^9/L Total bilirubin ≤ 1.25 x Upper Limit Normal ( ULN ) AST ( SGOT ) / ALT ( SGPT ) ≤ 2.5 x ULN liver metastasis Alkaline phosphatase &lt; 2 x ULN ( know liver bone disease ) Serum albumin &gt; 30 g/L , serum albumin = 30 g/L normal prothrombin time Creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) calculate CrCl ≥ 60 mL/min/1.73m^2 Women childbearing potential men must agree use adequate contraception prior study entry duration study participation Previous local therapy ( e.g. , chemoembolization bland embolization ) allow complete &gt; 6 week prior study entry . For patient , must either progression measurable disease document within treatment field , measurable progressive disease outside treatment field prior study entry . Previous chemotherapy and/or investigational agent allow complete &gt; 4 week prior study entry ( &gt; 6 week last regimen contain bischloroethyl nitrosourea ( BCNU ) mitomycin C ) . For patient receive systemic therapy prior study entry , must document progression measurable disease since receive systemic therapy prior study entry . Patients must disease currently amenable surgery . Prior surgery allow less 6 week prior study entry . History allergic reaction attribute compound similar chemical biologic composition 177LuDOTAJR11 assess medical record Life expectancy &lt; 6 month assess treat physician . Treatment shortacting somatostatin analog le 3 day Sandostatin® depot injection le 5 week scan treatment Uncontrolled , intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Women pregnant breastfeeding Toxicities prior therapy resolve grade 1 grade 0 Known CNS metastases and/or carcinomatous meningitis Active malignancy metastatic potential know carcinoid pancreatic NET within past three year &gt; 20 % bone marrow external beam radiotherapy and/or previous radioisotope therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiolabeled Somatostatin Antagonists</keyword>
	<keyword>68Ga-DOTA-JR11</keyword>
	<keyword>177Lu-DOTA-JR11</keyword>
	<keyword>Pet scan</keyword>
	<keyword>CT scan</keyword>
	<keyword>15-161</keyword>
</DOC>